| 000 | 01313 a2200349 4500 | ||
|---|---|---|---|
| 005 | 20250516105250.0 | ||
| 264 | 0 | _c20121218 | |
| 008 | 201212s 0 0 eng d | ||
| 022 | _a1744-8301 | ||
| 024 | 7 |
_a10.2217/fon.12.89 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGalvani, Elena | |
| 245 | 0 | 0 |
_aEGF receptor-targeted therapy in non-small-cell lung cancer: role of germline polymorphisms in outcome and toxicity. _h[electronic resource] |
| 260 |
_bFuture oncology (London, England) _cAug 2012 |
||
| 300 |
_a1015-29 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 |
_aCarcinoma, Non-Small-Cell Lung _xdrug therapy |
| 650 | 0 | 4 |
_aErbB Receptors _xantagonists & inhibitors |
| 650 | 0 | 4 | _aErlotinib Hydrochloride |
| 650 | 0 | 4 | _aGefitinib |
| 650 | 0 | 4 | _aGerm-Line Mutation |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aPolymorphism, Genetic |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xadverse effects |
| 650 | 0 | 4 |
_aQuinazolines _xadverse effects |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aPeters, Godefridus J | |
| 700 | 1 | _aGiovannetti, Elisa | |
| 773 | 0 |
_tFuture oncology (London, England) _gvol. 8 _gno. 8 _gp. 1015-29 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2217/fon.12.89 _zAvailable from publisher's website |
| 999 |
_c22026504 _d22026504 |
||